NIH Licensing Opportunity:
A Radiographic Marker that Displays Upright Angle in Degrees on Portable Chest X-rays
NIHLICENSING OPPORTUNITY NIH LICENSING OPPORTUNITY NIH LICENSING OPPORTUNITY LICENSING OPPORTUNITY NIH LICENSING OPPORTUNITY LICENSING OPPORTUNITY NIH LICENSING OPPORTUNITY LICENSING
One Million Solutions in Health™ has established a one-of-a-kind partnership with the United States’ National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) to increase awareness and understanding of NIH technologies by potential partners in the life science and healthcare industries.
This provides you with a front-row seat to hear about new technology and science from various scientists at the NIH. This is also your opportunity to participate in our proprietary Signature Square™ process, where end-users can evaluate the technology, ask questions and provide feedback directly to the scientist.
Radiographic marker that can significantly improve the diagnostic performance of portable chest and abdominal x-rays
Join us for this webinar that will introduce a groundbreaking radiographic marker that can significantly improve the diagnostic performance of portable chest (CXR) and abdominal x-rays.
– Currently, there is no quantitative marker to indicate the degree of the upright position for a patient. This technology introduces a simple, dynamic marker that can quantify the angle at a glance for the radiologist, allowing the best comparison of the patient’s condition over time.
– The technology improves performance of CXR, allowing reliable comparisons of the patient’s situation as treatment progresses. Thus, better therapies can be planned and unnecessary CT (Computerized Tomography) can be prevented.
– The technology improves care for Intensive Care Unit patients, as developing effusion and the need for immediate drainage (as one of many examples) can be more effectively assessed with the apparatus.
This device quantifies angulation of a patient, which provides reproducible and accurate results, which therefore provide for a better comparison of day-to-day improvement. This enhanced accuracy allows for better analysis and diagnosis.
For example, effusions appear differently with variations in the patient’s inclination. This makes effusions difficult to evaluate on serial exams. This can lead to an inaccurate diagnosis, potentially causing harm to the patient.
As one of the most common in-hospital procedures, the opportunity for this technology to revolutionize patient care is tremendous.
This is an opportunity to LICENSE THIS TECHNOLOGY, or participate in further collaborative work to enhance its development.
The Signature Square process is part of our Consortium infrastructure. Current member companies in the Technology Evaluation Consortium and SafeTEC include organizations like AstraZeneca, AbbVie, Amgen and Allergan, along with many others, including scientists, clinicians and investors in organizations around the world who help to evaluate this technology.
This is your opportunity to ask questions and provide feedback directly to the scientists by taking part in this Signature Square program.
Les R. Folio, DO, MPH, MSc (Rad), MAS
National Institutes of Health
Dawn Van Dam
Executive Director & CEO
One Million Solutions in Health™